Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda
Sumitomo Dainippon Pharma Co., Ltd and its US subsidiary, Sunovion Pharmaceuticals Inc., jointly filed patent infringement lawsuits on 14 January 2015 in the US District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd, Emcure Pharmaceuticals USA, Inc., and InvaGen Pharmaceuticals Inc. regarding their submissions of Abbreviated New Drug Applications (“ANDAs”) for generic copies of Latuda (lurasidone HCl) tablets. The lawsuits allege infringement of Sumitomo Dainippon Pharma’s US Patent No. 5,532,372 (“the ’372 Patent”).
The ’372 Patent is exclusively licensed to Sunovion in the US, and Sunovion has been marketing lurasidone HCl tablets in the US under the brand name Latuda since its launch in February 2011.
Due to the commencement of these lawsuits, the FDA approval of the ANDAs will be stayed at least until the earlier of 28 April 2018 (plus an additional 6 months thereafter if Sunovion is awarded a pediatric exclusivity extension) or the date of a district court decision finding the ’372 Patent invalid, unenforceable, or not infringed. Should Sumitomo Dainippon Pharma and Sunovion successfully enforce the ’372 Patent, ANDA approval should not occur at least until expiration of that patent on 2 July 2018 (plus an additional 6 months thereafter if Sunovion is awarded a pediatric exclusivity extension).
Sumitomo Dainippon Pharma and Sunovion believe that their patent position for Latuda is strong and they are prepared to vigorously protect their patent rights.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance